Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
The Present Efficacy of Multiple Sclerosis Therapeutics
Neurol 73:984-990, Klawiter,E.,et al, 2009